摘要
目的探究甲钴胺联合大秦艽汤治疗面神经炎患者的临床疗效。方法选取2021年1月—2024年4月收治的85例面神经炎患者作为研究对象,按照随机数字表法分为西药组(n=43)和中西药结合组(n=42)。西药组在常规治疗的基础上给予甲钴胺治疗,中西药结合组在西药组治疗的基础上联合大秦艽汤治疗,比较2组患者的临床疗效,治疗前后的中医症状积分、面神经功能情况[面部残疾指数(facial disability index,FDI)]、患侧面神经复合肌肉动作电位(compound muscle action potential of the affected facial nerve,CMAP)波幅及R1潜伏期、血清学指标[载脂蛋白A1(apolipoprotein A1,ApoA1)、脂蛋白(a)[lipoprotein(a),Lp(a)]及高密度脂蛋白(high-density lipoprotein,HDL)]及不良反应的发生情况。结果中西药结合组的治疗总有效率为92.86%,显著高于西药组的76.74%(P<0.05)。治疗后,2组患者的口角歪斜、面部松弛、耳后疼痛、舌木无味评分均显著下降,且中西药结合组均低于西药组(P<0.05)。治疗后,2组的躯体功能评分均显著升高,且中西药结合组高于西药组(P<0.05);社会生活功能评分均显著降低,且中西药结合组低于西药组(P<0.05)。治疗后,2组的CMAP波幅均显著升高,且中西药结合组高于西药组(P<0.05);R1潜伏期均显著降低,且中西药结合组低于西药组(P<0.05)。治疗后,2组的ApoA1、HDL水平均显著升高,且中西药结合组均高于西药组(P<0.05);Lp(a)显著降低,且中西药结合组低于西药组(P<0.05)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论甲钴胺联合大秦艽汤治疗面神经炎患者,可有效提高临床疗效,改善患者的FDI指数,调节血清ApoA1、Lp(a)、HDL的水平,且无明显不良反应,具有较高的临床应用价值。
Objective To explore the efficacy of Daqinjiao Decoction adjuvant therapy in patients with facial neuritis.Methods A total of 85 patients with facial neuritis in the hospital from January 2021 to April 2024 were selected and divided into western medicine group(mecobalamin on the basis of routine treatment,n=43)and Chinese-western medicine group(Daqinjiao Decoction on the basis of western medicine group,n=42)according to the random number table method.The clinical efficacy,traditional Chinese medicine(TCM)symptom scores,facial nerve function[facial disability index(FDI)],compound muscle action potential of the affected facial nerve(CMAP)amplitude and R1 latency of the affected side nerve and serological indicators[apolipoprotein A1(ApoA1),lipoprotein(a)[Lp(a)]and high-density lipoprotein(HDL)]before and after treatment and adverse reactions were compared between the 2 groups.Results The total effective rate of the treatment in Chinese-western medicine group was higher than that in western medicine group(92.86%vs.76.74%)(P<0.05).After treatment,the scores of deviated mouth,facial relaxation,post-auricular pain and tasteless tongue in the 2 groups were decreased(P<0.05),and the above scores in Chinese-western medicine group were lower than those in western medicine group(P<0.05).The score of physical function was increased in both groups after treatment(P<0.05),while the score of social life function was decreased(P<0.05),and there were statistical differences between groups after treatment(P<0.05).CMAP amplitude in both groups after treatment was elevated(P<0.05)while R1 latency was declined(P<0.05),and the differences between groups after treatment were statistically significant(P<0.05).After treatment,the levels of ApoA1 and HDL were enhanced in both groups(P<0.05),while Lp(a)was reduced(P<0.05),and the differences were statistically significant between the 2 groups(P<0.05).There was no statistical difference in the incidence rates of adverse reactions between the 2 groups(P>0.05).Conclusion Daqinjiao Decoction adjuvant therapy can effectively enhance the efficacy,improve the FDI index,and regulate the levels of serum ApoA1,Lp(a)and HDL in the treatment of facial neuritis,and it has no obvious adverse reactions.
作者
蔡军
王燕
王荣军
CAI Jun;WANG Yan;WANG Rongjun(Center Pharmacy of Medical Community He County Hospital of Traditional Chinese Medicine,Ma’anshan 238200,China;Department of Rehabilitation,He County Hospital of Traditional Chinese Medicine,Ma’anshan 238200,China)
出处
《西北药学杂志》
2025年第4期93-98,共6页
Northwest Pharmaceutical Journal
基金
马鞍山市中医药类科研课题立项项目(编号:MZH-2023-25)。
关键词
面神经炎
中西药结合疗法
大秦艽汤
甲钴胺
载脂蛋白A1
facial neuritis
integrated Chinese and western therapy
Daqinjiao Decoction
mecobalamin
apolipoprotein A1
